The Genomes2People Research Team manages several projects and collaborates on others, all noted below. Click on each project to learn about its goals and progress as well as easily access relevant scientific publications and media stories.
The second phase of the BabySeq Project, funded again by the NIH, is examining the use of whole genome sequencing to screen a diverse cohort of newborns for genetic childhood disease risk. BabySeq follows the pediatricians’ incorporation of genetic information into newborns’ medical care. This time focusing on a cohort that is representative of the general population, BabySeq aims to collect the data needed to examine what the risks and benefits of newborn genome sequencing might be as we imagine implementing it into everyday care.
The Personal Genome Sequencing Outcomes (PeopleSeq) Consortium, funded by the NIH, is one of the first large-scale longitudinal studies to examine the experiences, attitudes and outcomes of apparently healthy adults who have elected to obtain exome or genome sequencing. Data collected will provide valuable information on the potential benefits and costs of performing sequencing in healthy individuals, and key insights into the feasibility of using sequencing to create a more personalized and preventative model of medicine.
The pilot phase of the BabySeq Project, funded by the NIH, examined the use of whole exome sequencing to screen newborns for genetic childhood disease risk. BabySeq followed the pediatricians’ incorporation of genetic information into the baby’s medical care. BabySeq aimed to collect the data needed to examine what the risks and benefits of newborn genome sequencing might be as we imagined implementing into everyday care.
The MilSeq Project, funded by the Department of Defense through the Air Force Medical Support Agency, is a pilot study examining the process of incorporating whole exome sequencing (WES) into the United States Air Force (USAF) military health system. Active-duty service members of the USAF (Airmen) are enrolled into the study to undergo clinical WES.
Risk Evaluation and Education of Alzheimer’s Disease: the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN), funded by the NIH, is the first multi-site, randomized clinical trial to examine the impact of learning amyloid imaging results in cognitively normal individuals.
The MedSeq Project focused on integrating whole genome sequencing into clinical medicine and was the first clinical trial ever funded by the NIH to empirically study the use of whole genome sequencing in the practice of medicine. The Project was led by a multi-disciplinary team of more than 40 scientists.
The Impact of Personal Genomics (PGen) Study, funded by the NIH, was a survey of consumers from two U.S. companies providing direct-to-consumer genetic testing, using independent third-party data collection and analysis to provide data on who was ordering these tests and why, and potential benefits and risks.
The Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) Study, funded by the NIH, was a series of multi-site randomized controlled clinical trials that provided empirical data to address ethical, social and translational issues in genetic susceptibility testing for common diseases.
Collaborative projects are research efforts led by independent investigators who have partnered with the G2P Research Team. Click on each project to learn about its principal investigator, the project goals and progress as well as easily access relevant scientific publications and media stories.
The Genomes2Veterans Research Program at the Veterans Affairs (VA) Boston Healthcare System is run by director Jason Vassy, MD, MPH, SM, and bridges the expertise of Genomes2People and the mission of bringing 21st century medical care to Veterans.
The Econogenomics Working Group is a multidisciplinary group of investigators from multiple sites around the country with diverse clinical and methods expertise. Led by Kurt Christensen, PhD, the group has clinical expertise in genetics, pediatrics, and internal medicine in addition to methods expertise in genomics, pharmacoepidemiology, simulation modeling, cost-effectiveness, and health systems research.
We have assembled a Genomics & Life Insurance Working Group of experts to explore themes, challenges and benefits of educating life insurers about genetic and genomics concepts.
The Imagenetics METRICS Study, funded by Sanford Health, was launched in 2019 to evaluate the outcomes of the Sanford Chip Program, one of the first genetic tests offered as a clinical service to adult primary care patients in a major U.S. health care system. Lessons from this study will provide critical information about the benefits, risks, and challenges of integrating genetic testing into general patient care.